| Pharmacotherapy for the prevention of post-ERCP pancreatitis. | |
| | |
MedLine Citation:
|
PMID: 17266688 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Post-ERCP pancreatitis (PEP) is a potential complication of ERCP. Pharmacotherapy for prevention of PEP aims at reducing basal sphincter pressure and contractility or a decrease in pancreatic secretion to reduce intraductal pressure. Timing and route of administration of drugs are critical to ensure maximum benefits from medications. Pancreatic stenting offers an alternative to decompress the pancreas and is effective in reducing PEP in high-risk patients. |
| | |
Authors:
|
Erina Foster; Joseph Leung |
Related Documents
:
|
3707228 - Physiologic evaluation of esophageal function in patients with achalasia and diffuse es... 15352918 - Differential effects of two types of antidepressants, amitriptyline and fluoxetine, on ... 17895358 - Oesophageal high-resolution manometry: moving from research into clinical practice. 14520278 - Effects of droperidol on the pancreatic and biliary sphincters. 8476238 - Physiologic role of the normal pericardium. 2655688 - Does a selective 5-hydroxytryptamine antagonist (ici 169, 369) lower blood pressure in ... |
Publication Detail:
|
Type: Comment; Editorial |
Journal Detail:
|
Title: The American journal of gastroenterology Volume: 102 ISSN: 0002-9270 ISO Abbreviation: Am. J. Gastroenterol. Publication Date: 2007 Jan |
Date Detail:
|
Created Date: 2007-02-01 Completed Date: 2007-03-16 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 0421030 Medline TA: Am J Gastroenterol Country: United States |
Other Details:
|
Languages: eng Pagination: 52-5 Citation Subset: IM |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Cholangiopancreatography, Endoscopic Retrograde
/
adverse effects* Gastrointestinal Agents / therapeutic use* Humans Octreotide / therapeutic use* Pancreatitis / etiology*, prevention & control* Randomized Controlled Trials as Topic |
| Chemical | |
Reg. No./Substance:
|
0/Gastrointestinal Agents; 83150-76-9/Octreotide |
| Comments/Corrections | |
Comment On:
|
Am J Gastroenterol. 2007 Jan;102(1):46-51
[PMID:
17266687
]
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Effect of octreotide administration in the prophylaxis of post-ERCP pancreatitis and hyperamylasemia...
Next Document: Effect of lowering HBV DNA levels by initial antiviral therapy before adding immunomodulator on trea...